Literature DB >> 8598323

Effects of cytokines combined with high-dose gamma irradiation on the expression of major histocompatibility complex molecules and intercellular adhesion molecule-1 in human ovarian cancers.

A D Santin1, G S Rose, J C Hiserodt, J Fruehauf, L M Eck, R I Garcia, V Schranz, P J Disaia, S Pecorelli, G A Granger.   

Abstract

Tumor cells from 7 freshly isolated human ovarian tumors and 2 continuous human ovarian cancer cell lines were analyzed for their surface expression of MHC class-1, class 11 and ICAM-1 surface antigens before and after exposure to gamma-irradiation and/or the cytokines TNF-alpha plus IFN-gamma. All 7 fresh tumors expressed high levels of MHC class 1 and 1CAM-1 antigens, and levels were markedly up-regulated after exposure to TNF-alpha plus IFN-gamma Similarly, class-11 antigens were either induced (3 out of 7 tumors) or significantly up-regulated by TNF-alpha plus IFN-gamma. Exposure to high doses of gamma-irradiation also increased the expression of MHC class-1 and ICAM-1 antigens, albeit to a modest degree. MHC class 1 and ICAM-1 antigens expression was much lower on continuous human ovarian cell lines than on the fresh tumors. Exposure of these cells to TNF-alpha plus IFN-gamma markedly up-regulated antigen expression to levels comparable to those expressed on the freshly isolated tumors. With the established ovarian cell lines, removal of cytokines caused a rapid down-regulation of antigen expression to basal levels within 6 days, while in the fresh tumors a low level of up-regulation was still present at this time. In contrast, exposure to cytokines followed by high-dose gamma-irradiation resulted in a highly significant and long-lasting expression of each surface antigen which was either up-regulated or induced by the cytokines. These data indicated that the combination of these modalities may be beneficial in generating optimal antigen expression for use of tumor cells in vaccine studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8598323     DOI: 10.1002/(SICI)1097-0215(19960301)65:5<688::AID-IJC21>3.0.CO;2-2

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Radiation-induced tumor neoantigens: imaging and therapeutic implications.

Authors:  Christopher D Corso; Arif N Ali; Roberto Diaz
Journal:  Am J Cancer Res       Date:  2011-01-25       Impact factor: 6.166

2.  In Vitro and In Vivo Activity of IMGN853, an Antibody-Drug Conjugate Targeting Folate Receptor Alpha Linked to DM4, in Biologically Aggressive Endometrial Cancers.

Authors:  Gary Altwerger; Elena Bonazzoli; Stefania Bellone; Tomomi Egawa-Takata; Gulden Menderes; Francesca Pettinella; Anna Bianchi; Francesco Riccio; Jacqueline Feinberg; Luca Zammataro; Chanhee Han; Ghanshyam Yadav; Katherine Dugan; Ashley Morneault; Jose F Ponte; Natalia Buza; Pei Hui; Serena Wong; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2018-02-13       Impact factor: 6.261

3.  Impact of Activation of EGFL7 within Microenvironment of High Grade Ovarian Serous Carcinoma on Infiltration of CD4+ and CD8+ Lymphocytes.

Authors:  Jacek J Sznurkowski; Anton Żawrocki; Natalia Krawczyńska; Michał Bieńkowski; Bartosz Wasąg; Wojciech Biernat
Journal:  Medicina (Kaunas)       Date:  2022-04-24       Impact factor: 2.948

4.  Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.

Authors:  Romana Koppensteiner; Eleftherios P Samartzis; Aurelia Noske; Adriana von Teichman; Ioannis Dedes; Myriam Gwerder; Patrick Imesch; Kristian Ikenberg; Holger Moch; Daniel Fink; Manuel Stucki; Konstantin J Dedes
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

Review 5.  Radiation, inflammation and the immune response in cancer.

Authors:  Kelly J McKelvey; Amanda L Hudson; Michael Back; Tom Eade; Connie I Diakos
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 6.  Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity.

Authors:  Barbara Seliger
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

7.  In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma.

Authors:  K El-Sahwi; S Bellone; E Cocco; M Cargnelutti; F Casagrande; M Bellone; M Abu-Khalaf; N Buza; F A Tavassoli; P Hui; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

8.  Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.

Authors:  A D Santin; S Bellone; A Ravaggi; J J Roman; S Pecorelli; G P Parham; M J Cannon
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

Review 9.  Radiotherapy and the tumor stroma: the importance of dose and fractionation.

Authors:  Turid Hellevik; Iñigo Martinez-Zubiaurre
Journal:  Front Oncol       Date:  2014-01-21       Impact factor: 6.244

10.  Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas.

Authors:  Salvatore Lopez; Emanuele Perrone; Stefania Bellone; Elena Bonazzoli; Burak Zeybek; Chanhee Han; Joan Tymon-Rosario; Gary Altwerger; Gulden Menderes; Anna Bianchi; Luca Zammataro; Aranzazu Manzano; Paola Manara; Elena Ratner; Dan-Arin Silasi; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Francesco Raspagliesi; Roberto Angioli; Natalia Buza; Pei Hui; Heather M Bond; Alessandro D Santin
Journal:  Oncotarget       Date:  2020-02-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.